1129 GMT - Sanofi's mixed results for its itepekimab drug candidate increase the importance of a successful outcome in a late-stage trial for another investigational drug, amlitelimab, for atopic dermatitis, Jefferies analysts say in a research note. The French drugmaker and U.S. partner Regeneron last week said itepekimab missed the primary goal of a late-stage clinical trial in former smokers with chronic obstructive pulmonary disease, but met the key objective in another study. These results likely increase investors' focus on results for an amlitelimab phase 3 study due in the second half of 2025, Jefferies says. Amlitelimab is now widely seen as the key program to help offset the loss of exclusivity for Sanofi and Regeneron's blockbuster anti-inflammatory drug in 2031 and 2032, the analysts say. Sanofi shares fall 1.7%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 07:29 ET (11:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.